Nia Impact Advisors, LLC Seagen Inc. Transaction History

Nia Impact Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$127.59 - $203.08 $64,432 - $102,555	-505 Reduced 29.6%	1,201 $243,000
Q4 2022 Feb 09, 2023	SELL	$117.37 - $139.17 $78,990 - $93,661	-673 Reduced 28.29%	1,706 $219,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $732,622 - $975,475	-5,416 Reduced 69.48%	2,379 $325,000
Q2 2022 Aug 05, 2022	SELL	$108.81 - $179.33 $810,090 - $1.34 Million	-7,445 Reduced 48.85%	7,795 $1.38 Million
Q1 2022 May 11, 2022	SELL	$119.61 - $157.85 $67,220 - $88,711	-562 Reduced 3.56%	15,240 $2.2 Million
Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $248,642 - $332,859	-1,744 Reduced 9.94%	15,802 $1.97 Million
Q3 2021 Nov 16, 2021	BUY	$142.45 - $169.82 $130,769 - $155,894	918 Added 5.52%	17,546 $2.98 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $98,068 - $116,958	726 Added 4.57%	16,628 $2.63 Million
Q1 2021 Jun 16, 2021	BUY	$137.51 - $190.8 $168,587 - $233,920	1,226 Added 8.35%	15,902 $2.21 Million
Q4 2020 Jan 25, 2021	BUY	$164.63 - $211.93 $2.42 Million - $3.11 Million	14,676 New	14,676 $2.59 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Nia Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nia Impact Advisors, LLC with notifications on news.